Estrogen Receptor 1 Gene (ESR1) rs2234693 Polymorphism and Breast Cancer Risk in Saudi Women

Razan Jamaan Al-Amri¹, Mohammad Kdaimes H Alotibi¹, Rawya Ibrahim AL-Raddadi¹, Weam Talal Yahya Shebli¹, Emad Ibrahim Yagoub Fallatah², Ahmed Safar Alhujaily3, Hiba Salaheldin Mohamed¹4*

Abstract

Objective: The present study aimed to determine the role of ESR1 gene rs2234693 T/C polymorphism (PvuII) in the susceptibility to breast cancer and to assess the association of this polymorphism within presence or absence of estrogen, progesterone receptors, human epidermal growth factor receptor 2 (HER2) and with premenopausal and postmenopausal age in Saudi women. Methods: The study was a retrospective case-control study. In this study, 137 breast cancer and 98 normal breast paraffin embedded tissues were included. DNA was extracted and ESR1 gene rs2234693 T/C polymorphism was genotyped by PCR-RFLP. Genetic association tests were performed. Results: The results showed no significant difference in distribution of rs2234693 T/C alleles and genotypes frequencies. Odd ratios (95% CI) were 1.15 (0.8-1.66) and 1.06 (0.5-1.98) and p values were 0.51 and 0.87, respectively. The genotypes and alleles frequencies within different hormonal receptors groups and ages of menopause showed no signification association (odd ratios were less or close to 1 and p values > 0.05). Conclusion: ESR1 gene rs2234693 T/C polymorphism was not associated with susceptibility to breast cancer and different menopausal, hormone receptors, and HER2 status in breast cancer patients. Further analysis using larger sample size will be needed to assess the association of different polymorphisms within the gene and risk of breast cancer.

Keywords: Genetic variant- ESR1- breast cancer- Saudi Arabia

Introduction

Breast cancer (BC) is a serious health issue, causing changes within the body cells and out of control cell grow (Alotaibi et al., 2018; Saggu et al., 2015). Saudi Cancer Registry (SCR) recorded a total of 6,922 female BC cases between January 2001 and December 2008. The number of female BC cases was 1,152, 1,308, and 1,473 in 2008, 2009, and 2010, respectively. In 2010, BC ranked first (5,378 cases, 27.4%) among females with newly diagnosed cancers (Saggu et al., 2015; Saudi Cancer Registry, 2005). In 2018, IARC reported BC as the most prevalent cancer in Saudi Arabia with 3629 new cases out of all other cancers among women (https://geo.iarc.fr/today/data/factsheets/populations/682-saudi-arabia-fact-sheets.pdf.).

Studies have shown that BC is a complex disease and factors such as gender, age, ethnicity, family history, genetic factors, menopausal status, radiation exposure, alcohol, and exposure to high dose of estrogen are associated with the risk of developing BC (Nindrea et al., 2017). Effects of estrogen are mediated through two distinct nuclear receptors, namely estrogen receptor alpha (ERα) encoded by ESR1 gene and estrogen receptor beta (ERβ) encoded by ESR2 gene (Deroo and Korach, 2006). Estrogen and its receptor ER1 have major function in development and progression of cancer. ER1 is an important mediators of hormonal response and a target for BC hormonal treatments (Debeb and Berihu, 2015). It also stimulates mammary epithelial tissue proliferation and differentiation through combining with estrogen (Clemons and Goss, 2001). ESR1 gene, located on chromosome 6q25.1, consists of eight exons and seven introns (Ponglikitmongkol et al., 1988). ESR1 gene is a low-penetrance BC susceptibility gene. It may increase the likelihood of accumulation of genetic mutations occurring throughout cellular division. It functions as a ligand and stimulates cell proliferation and controls cell growth and cell death by binding to both endogenous and exogenous hormones. Genome-wide association studies have identified several single nucleotide polymorphisms (SNPs) within ESR1 gene that are associated with predisposition...
to BC. *ESR1* rs2234693 (PvuII) polymorphism is located in intron one and it is one of the most characterized SNPs of *ESR1* gene (Hill et al., 1989). It is also associated with increased risk of BC and other diseases in which estrogen is implicated (Deroo and Korach, 2006). Possible purposeful mechanism attributed to the present polymorphism includes a change in the expression of the *ESR1* gene by altering the transcription factor binding sites and affecting alternative splicing of the *ESR1* gene. However, the allele variant has been shown to be associated with BC risk in different populations (Chauhan et al., 2019). The present study aimed to find out the possible role of *ESR1* gene rs2234693 T/C polymorphism in the susceptibility to BC. We also tried to evaluate the association of this polymorphism within presence or absence of estrogen, progesterone receptors, and human epidermal growth factor receptor 2 (HER2) and menopausal status.

### Materials and Methods

#### Study design and samples

Breast tissue samples of Saudi women were collected from King’s Fahad Hospital. All samples were archive, antonyms, and paraffin-embedded (FFPE) tissues. Clinical data of each patient was retrieved from King Fahad Hospital database. This hospital-based case-control study included 137 histopathological confirmed BC cases and 98 benign tissue samples as controls. The cases and controls were matched in age. Samples with different BC subtypes, including different receptors status ER, PR, HER2, and triple-negative (ER-, PR-, HER2-), were included.

#### DNA extraction and genotyping

The DNA was extracted from 5 to 8 pieces of 10 μm thickness sections of paraffin embedded tissue. Through incorporation of several steps of heating and shaking, modified phenol-chloroform protocol method was used. The primers were designed to amplify *ESR1* gene rs2234693 (T/C) polymorphism. Forward primer was 5’-GGGTATGTGGCAATGACGT-3’ and reverse primer was 5’-GACCAATGCTCATCCAACTC-3’ (Macrogen Company, South Korea) with an expected product size of 164 bp. The amplification was performed using T100™ Thermal Cycler (Bio-Rad, Germany) instrument in a total volume of 25 μL by Maxime PCR PreMix Kit (Intron biotechnology, South Korea). The PCR mix consisted of 2.5 mM dNTPs, 5 μl i-Taq TM polymerase, 1X reaction buffer, gel loading buffer, 1 μl of 10 mM of each primer, and 1 μl of template DNA (100 ng/μl). PCR conditions consisted of 35 cycles following a hot start at 95°C for 3 minutes. Each cycle included the following three steps: DNA denaturation (30 second at 94°C), primer annealing (30 second at 62°C), and primer extension (1 minute at 72°C). There was a final extension cycle for 5 minutes at 72°C. The size of the amplified product was determined using 1% agarose gel electrophoresis. The amplified PCR product was digested by the PvuII enzyme (Thermo Fisher Scientific, USA). The DNA fragments were separated using 3% low melting agarose gel. Restriction digestion by PvuII produced two fragments of 108 and 56 bp.

#### Sequencing

Six samples were selected from three different genotypes (Homozygous wild type T/T, Heterozygous T/C, and Homozygous mutant C/C). PCR was performed in volume of 50 μl and sent to Macrogen (Korea) company for sequence analysis, using same forward and reverse primers, to confirm RFLP genotype results.

#### Genetic statistical analysis

Allele and genotype frequencies of PvuII polymorphism of the genotypes were calculated. Deviation from Hardy Weinberg equilibrium was tested. Genetic association tests were performed using AssociaTORRRR software (https://www.genecalculators.net/associatorrr-cc.html). Odd ratio (OR) with 95% confidence intervals (CI) was used to express association. P-value <0.05 was considered statistically significant.

### Results

**Demographic information and clinicopathological features of BC patients**

The average age of our patients was 51.2±14 and 59 (43.1%) ones aged < 50 and 70 (51.1%) aged ≥50. Invasive-infiltrating ductal carcinoma was the most

![Figure 1. Representatives gel for PCR product. Lane 1, represents 100bp DNA molecular weight marker; Lane 2 to 7, PCR product (164bp); Lane 8, negative control.](image-url)
Estrogen Receptor 1 Gene (ESR1) rs2234693 Polymorphism and Breast Cancer Risk in Saudi Women

The PCR product for ESR1 gene rs2234693 T/C polymorphism generated size band of 164bp (Figure 2). The results on hormone receptor status showed that 74 (54%) out of 119 patients were ER-positive, 60 (43.8%) were PR-positive, and 38 (27.7%) were HER2-positive. Molecular subtyping using surrogate immunohistochemistry (IHC) markers showed that luminal A subtype predominated in patients (43.8%), followed by HER2-like (15.3%), and luminal B (12.4%), while triple-negative subtype was represented in 13.9% of the patients.

Table 1. Genotype Frequencies of ESR1 Gene rs2234693 T/C Polymorphism in Breast Cancer Patients versus Controls

| Allele/Genotype | Cases (frequency) n = 137 | Controls (frequency) n = 98 | OR (95%CI) | P* value |
|-----------------|---------------------------|-----------------------------|------------|----------|
| T               | 133 (0.49)                | 102 (0.52)                  | 1.15 (0.8-1.66) | 0.51     |
| C               | 141 (0.51)                | 94 (0.48)                   |            |          |
| T/T             | 33 (0.24)                 | 26 (0.27)                   | 1.06 (0.56-1.98) | 0.87     |
| T/C             | 67 (0.49)                 | 50 (0.51)                   |            |          |
| C/C             | 37 (0.27)                 | 22 (0.22)                   |            |          |

ESR1, Estrogen receptor 1 gene; OR, odd ratio (OR≤1 or close to 1 means the SNP does not affect odds of disease outcome); CI, Confidence interval; n, Total number of samples; P* value, 2 tailed P value- Fisher's Exact Test. Cut off ≤ 0.05

**RCR-RFLP**

The PCR product for ESR1 gene rs2234693 T/C polymorphism generated size band of 164bp (Figure 3).
1). Genotyping using the PvuII enzyme showed three different patterns (Figure 2).

**Sequencing**

The sequencing results obtained from Macrogen (Korea) company confirmed our results on different genotypes (Figure 3).

**Genetic statistical analysis**

The genetic analysis demonstrated similar distribution of PvuII polymorphism alleles and genotypes frequency between controls and cases (Table 1). The genotype frequencies revealed 0.24 of wild homozygous (TT), 0.49 of heterozygous (TC), and 0.27 of mutant homozygous (CC) in the cases. In the control group, the genotype frequencies were 0.27 of wild homozygous (TT), 0.51 of heterozygous (TC), and 0.22 of mutant homozygous (CC). The Minor allele frequencies were (C allele) 0.51 and 0.48 in cases and controls, respectively. There was no significant association between ESR1 gene rs2234693 T > C polymorphism and susceptibility to BC. Table 2 depicts a summary on the distribution of genotypes by menopausal status and hormonal receptor status. The results did not suggest any genetic association between menopausal status and predisposition to BC. No association was detected between ESR1 gene rs2234693 within presence or absence of the estrogen and progesterone hormones and HER2 in tumor samples (Table 2). The genotype and allele frequencies were in Hardy–Weinberg equilibrium where p values were >0.05.

### Table 2. Polymorphism of ESR1 PvuII and Breast Cancer Risk by a Menopausal Status and Receptors Statues

| Genotype/allele | Controls (frequency) | ER+ cases | ER− cases | Controls vs. ER+ OR (95%CI) | Controls vs. ER− OR (95%CI) |
|-----------------|----------------------|-----------|-----------|----------------------------|----------------------------|
| T               | 102 (0.52)           | 79 (0.53) | 44 (0.49) | 0.95 (0.62–1.45)            | 1.13 (0.69–1.87)           |
| C               | 94 (0.48)            | 69 (0.47) | 46 (0.51) | P = 0.83                   | P = 0.7                    |
| TT              | 26 (0.27)            | 22 (0.3)  | 10 (0.22) | 0.83 (0.41–1.7)            | 1.25 (0.52–3)              |
| TC              | 50 (0.51)            | 35 (0.47) | 24 (0.53) | P = 0.87                   | P = 0.67                   |
| CC              | 22 (0.22)            | 17 (0.23) | 11 (0.24) |                           |                           |

| Genotype/allele | Controls (frequency) | PR+ Cases | PR− cases | Controls vs. PR+ OR (95%CI) | Controls vs. PR− OR (95%CI) |
|-----------------|----------------------|-----------|-----------|----------------------------|-----------------------------|
| T               | 102 (0.52)           | 66 (0.55) | 56 (0.48) | 0.89 (0.56–1.40)            | 1.16 (0.73–1.84)            |
| C               | 94 (0.48)            | 54 (0.45) | 60 (0.52) | P = 0.64                   | P = 0.56                    |
| TT              | 26 (0.27)            | 20 (0.33) | 12 (0.20) | 0.68 (0.32–1.43)            | 1.39 (0.61–3.1)             |
| TC              | 50 (0.51)            | 26 (0.43) | 32 (0.55) | P = 0.34                   | P = 0.54                    |
| CC              | 22 (0.22)            | 14 (0.23) | 14 (0.24) |                           |                            |

| Genotype/allele | Controls (frequency) | HER+ cases | HER− cases | Controls vs. HER+ OR (95%CI) | Controls vs. HER− OR (95%CI) |
|-----------------|----------------------|-----------|-----------|----------------------------|-----------------------------|
| T               | 102 (0.52)           | 38 (0.50) | 84 (0.53) | 1.09 (0.64–1.84)            | 0.98 (0.65–1.49)            |
| C               | 94 (0.48)            | 38 (0.50) | 76 (0.48) | P = 0.79                   | P = 1                       |
| TT              | 26 (0.27)            | 11 (0.29) | 21 (0.26) | 0.67 (0.31–1.86)            | 1.04 (0.51–2.1)             |
| TC              | 50 (0.51)            | 16 (0.42) | 42 (0.53) | P = 0.64                   | P = 1                       |
| CC              | 22 (0.22)            | 11 (0.29) | 17 (0.21) |                           |                            |

| Genotype/allele | Controls (frequency) | TNBC cases | Controls vs. TNBC OR (95%CI) |
|-----------------|----------------------|------------|-----------------------------|
| T               | 102 (0.52)           | 18 (0.47)  | 1.21 (0.60–2.42)            |
| C               | 94 (0.48)            | 20 (0.53)  | P = 0.72                    |
| TT              | 26 (0.27)            | 3 (0.16)   | 2.08 (0.54–8.03)            |
| TC              | 50 (0.51)            | 12 (0.63)  | P = 0.37                    |
| CC              | 22 (0.22)            | 4 (0.21)   |                            |

| Genotype/allele | Pre controls | Pre cases | Post controls | Post cases | Controls vs. Pre OR (95%CI) |
|-----------------|--------------|-----------|---------------|-------------|-----------------------------|
| T               | 79 (0.53)    | 55 (0.47) | 14 (0.47)     | 73 (0.51)   | 1.31 (0.81–2.13)            |
| C               | 69 (0.47)    | 63 (0.53) | 16 (0.53)     | 69 (0.49)   | P = 0.32                    |
| TT              | 21 (0.28)    | 13 (0.22) | 3 (0.20)      | 19 (0.27)   | 1.27 (0.54–2.05)            |
| TC              | 37 (0.50)    | 29 (0.49) | 8 (0.53)      | 35 (0.49)   | P = 0.68                    |
| CC              | 16 (0.21)    | 17 (0.29) | 4 (0.27)      | 17 (0.24)   |                            |

ESR1, Estrogen receptor1 gen; ER, Estrogen receptor; PR, Progesterone receptor; HER2, Human epidermal receptor 2 (HER2); TNBC, Triple negative breast cancer; Pre, Premenopausal; Post, Postmenopausal; N, number of samples; OR, odd ratio. (OR<1 or close to 1 means the SNP does not affect odds of disease outcome); CI, confidence interval; P* value, 2 tailed P value- Fisher’s Exact Test. Cut off ≤ 0.05.
Discussion

BC is a multifactorial disease and it is not yet fully understood. GWAS has shown that the fundamental BC mechanisms are composed of genetic and environmental factors, and certain SNPs within susceptibility genes may have an impact on the development of BC (Albalawi et al., 2019). Numerous clinical studies have investigated SNPs within ESR1 gene while the most widely studied polymorphisms of ESR1 is rs2234693 (Abd Ellatif et al., 2016). This was the first study conducted in KSA investigating ESR1 gene PvuII polymorphism and BC. The changes in ESR1 gene expression are possible functional mechanisms attributed to PvuII polymorphism (Anghel et al., 2010). It was reported that substitution of T by C led to loss of PvuII restriction site, and the resulted C allele produced myb transcription factor binding site, significantly increasing transcription compared to the T allele (Herrington et al., 2002). Several diseases, including BC (Zhang et al., 2015; Zhang et al., 2018), endometrial cancer (Ashton et al., 2009), prostate cancer (Li et al., 2017), Alzheimer’s disease (Cheng et al., 2014), endometriosis and leiomyoma (Hsieh et al., 2007), and hepatocellular and gallbladder cancer (Sun et al., 2015) were assessed for probable association with PvuII polymorphism. In this study, no genetic association was found between PvuII polymorphism and BC risk. Similar results were shown in different populations, including Korean, Swedish, Americans, and Portuguese (Shin et al., 2003; Sonestedt et al., 2009; Alves et al., 2010; Clendenen et al., 2013). The PvuII polymorphism of the ESR1 gene was associated with susceptibility to BC in different population such as Chinese, Indian, and Egyptian (Cai et al., 2003; Abd Ellatif et al., 2016; Chauhan et al., 2019). There are contrasting results in this regard. Some studies demonstrated that ESR1 gene PvuII polymorphism was significantly associated with the lower risk of BC in Asians but not in Caucasians populations (Zhang et al., 2018). In a Meta-analysis, it was yielded that CC genotype was associated with an elevated risk of BC. However, TT or CT genotypes increased this risk in European and Caucasian (Hu et al., 2017). In different studies, PvuII ‘C’ allele was associated with high risk of BC in Asians, but with no risk in Euro-Americans population (Lu et al., 2013). This findings indicate that ethnicity and geographic location can contribute to the breast carcinogenesis (Zhang et al., 2015). The results of stratified analysis in this study did not reveal any genetic association between menopausal, hormonal, and growth receptors status and susceptibility to BC. Different studies indicated that menopausal status had an effect on estrogen production, cell signaling, and metabolism (Li and Xu, 2012). Several meta-analysis studies indicated that the ESR1 PvuII polymorphism was associated with high risk of BC in pre-menopausal in comparison with post-menopause women (Cai et al., 2003; González-Zulueta Ladd et al., 2008). However, many studies (Shin et al., 2003; González-Mancha et al., 2008; Anghel et al., 2010), including this study, did not show any genetic associations between menopausal status and increased risk of BC. The PvuII polymorphism was associated with ER expression in BC patients (Hill et al., 1989). In another study, ER status was not associated with susceptibility to BC, and PvuII C allele was found in high frequency in patients with PR negative (Anderson et al., 1994). This association was not found in the present study. Nevertheless, our results were in agreement with many studies in different populations, including Caucasian, Chinese, and Portuguese populations (Cai et al., 2003; Alves et al., 2010; Anghel et al., 2010).

In conclusion, these results indicated that ESR1 rs2234693 T/C polymorphism was not associated with susceptibility to BC in Saudi women. It is likely that ethnic variation and environmental influences among different populations have an effect on association between SNPs and possible risk of BC. Further studies are needed to confirm this finding and assess the association of other polymorphisms within ESR1 gene with risk of BC.

Ethic statement

All study procedures were agreed by Taibah University, College of Dentistry Research Ethics Committee (TUCDREC/20170607), and from the Department Research Committee at King Fahd Hospital (ADCARE), Madinah.

Acknowledgements

We are thankful to Departments of Histopathology and Oncology at King Fahd Hospital in Al-Madinah. Special thanks go to Mr. Mayyas Ali Jamal, a medical laboratory technician at Histopathology laboratory at King Fahd Hospital. This study was part of an approved thesis at Taibah University.

Authors contribution

HSM and MKHA contributed to conception and design of the study. RJA carried out the experimental work and assisted with data analysis. WTYS and RIA assisted with samples, data collection and DNA extraction. ASA and EIYF were the project clinicians facilitated acquisition of data. ASA conducted histopathological examination and provided samples. RJA and HSM prepared the manuscript. All authors read, commented on, and approved the final manuscript.

Funding Statement

No fund was received for this study

Conflict of Interest

The authors do not have any conflict of interest to declare.

References

Abd Ellatif M, Zahran MA, Denaiwar A, Elbaz A, Abdel Azeez HA (2016). Study of polymorphism of the estrogen receptor alpha gene as a genetic marker for the risk of breast cancer. JCEBS, 4, 16–22.

Albalawi IA, Mir R, FM AD (2019). Utility of amplification-refractory mutation system for the detection clinically significant estrogen and progesterone receptors gene
variations in breast cancer patients in Saudi Arabia. *IAJPS*, 6, 4734–47.

Alotaibi RM, Rezk HR, Juliana CI, Guire C (2018). Breast cancer mortality in Saudi Arabia: modelling observed and unobserved factors. *PLoS One*, 13, e0206148.

Alves SM, Mesquita L, Sousa R, Peralta F, Silva HC (2010). Polymorphisms of estrogen receptors, ER α and GPR30: association with breast cancer susceptibility and prognosis. *BMC Proc*, 4, 6.

Anderson TL, Heimdal KR, Skrede M, et al (1994). Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. *Hum Genet*, 94, 665–70.

Anghel A (2010). Estrogen receptor alpha polymorphisms: correlation with clinicopathological parameters in breast cancer. *Neoplasma*, 57, 306–15.

Ashton KA (2009). Estrogen receptor polymorphisms and the risk of endometrial cancer. An *Int J Gynecol Obstet*, 116, 1053–61.

Cai Q (2003). Genetic polymorphisms in the estrogen receptor α gene and risk of breast cancer: results from the Shanghai breast cancer study. *Cancer Epidemiol Biomarkers Prev*, 12, 853–9.

Chauhan P, Yadav R, Kaushal V, Kadian L (2019). Evaluation of genetic polymorphism in estrogen receptor α gene as breast cancer risk. *Biomed Res*, 30, 72–7.

Cheng D, Liang B, Hao Y, Zhou, W (2014). Estrogen receptor α gene polymorphisms and risk of Alzheimer’s disease: evidence from a meta-analysis. *Clin Interv Aging*, 9, 1031–8.

Clemens M, Goss P (2001). Estrogen and the risk of breast cancer. *N Engl J Med*, 344, 276–85.

Clendenen T (2013). Genetic variants in hormone-related genes and risk of breast cancer. *PLoS One*, 8, e69367.

Debeo YG, Berihu BA (2015). Review on the role of estrogen receptors in breast cancer. *Int J Pharm Sci Res*, 6, 1100–4.

Deroo BJ, Korach KS (2006). Estrogen receptors and human disease. *J Clin Invest*, 116, 561–70.

González-Mancha R (2008). Analysis of the ERalpha germline PvuII marker in breast cancer risk. *Med Sci Monit*, 14, 136–43.

González-Zuloeta Ladd AM (2008). Estrogen receptor alpha polymorphisms and postmenopausal breast cancer risk. *Breast Cancer Res Treat*, 107, 415–9.

Herrington DM (2002). Common Estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. *Circulation*, 105, 1879–82.

Hill SM, Fuqua SAW, Chamness GC, Greene GL, McGuire WL (1989). Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. *Cancer Res*, 49, 145–8.

Hsieh YY, Wang YK, Chang CC, Lin CS (2007). Estrogen receptor α-351 XbaI*G and -397 PvuI*C-related genotypes and alleles are associated with higher susceptibilities of endometriosis and leiomyoma. *Mol Hum Reprod*, 13, 117–22.

Hu X (2017). Association of three single nucleotide polymorphisms of ESR1 with breast cancer susceptibility: a meta-analysis. *J Biomed Res*, 31, 213–25.

Li G, Yang M, Li X, Deng S (2017). Comprehensive assessment of the association between estrogen receptor of alpha polymorphisms and the risk of prostate cancer: evidence from a meta-analysis. *Oncotarget*, 8, 102310–20.

Li LW, Xu L (2012). Menopausal status modifies breast cancer risk associated with ESR1 PvuII and XbaI polymorphisms in asian women: A HuGE review and meta-analysis. *Asian Pac J Cancer Prev*, 13, 5105–11.

Lu H (2013). Estrogen receptor alpha gene polymorphisms and breast cancer risk: a case-control study with meta-analysis combined. *Asian Pac J Cancer Prev*, 14, 6743–9.

Nindrea RD, Aryandono T, Lazuard L (2017). Breast cancer risk from modifiable and non-modifiable risk factors among women in Southeast Asia: a meta-analysis. *Asian Pac J Cancer Prev*, 18, 3201–6.

Ponglikitmongkol M, Green S, Chambon P (1988). Genomic organization of the human oestrogen receptor gene. *EMBO J*, 7, 3385–8.

Saggu S, Rehman H, Abbas ZK, Ansari AA (2015). Recent incidence and descriptive epidemiological survey of breast cancer in Saudi Arabia. *Saudi Med J*, 36, 1176–80

Saudi Cancer Registry Report (2005). Saudi Cancer Registry, Saudi Oncology Society. Available from: http://www.scr.org.sa/reports/SCR2005.pdf.

Shin A (2003). Estrogen receptor alpha gene polymorphisms and breast cancer risk. *Breast Cancer Res Treat*, 80, 127–31.

Sonestedt E (2009). The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes. *J Nutr*, 139, 993–1001.